This is a routine promotional update with no new material data. The stock is a micro-cap with a history of high volatility. Monitor for the mid-2026 DURIPANC report and any regulatory milestones, but do not trade on this release alone.
Price Chart
Executive Summary
AIM ImmunoTech issued a press release highlighting a KOL segment discussing Ampligen for late-stage pancreatic cancer. The release touts positive interim data from the DURIPANC Phase 2 study and the Named Patient Program, showing improvements in progression-free and overall survival versus historical controls. However, this is a forward-looking promotional update with no new regulatory filing, no hard financial data, and no catalyst date beyond an expected mid-2026 report, making it a low-impact event for a micro-cap stock.
Key Facts
- Press release announces a KOL Connect segment discussing Ampligen for late-stage pancreatic cancer.
- References positive interim data from the DURIPANC Phase 2 study (with AstraZeneca's Imfinzi) and the Named Patient Program.
- Named Patient Program data shows PFS of 12.6 months vs. 8.6 months historical control and OS of 19.7 months vs. 12.5 months.
- Mid-Year 2026 report, completion of enrollment, and milestones expected in June 2026.
- No new financial data, regulatory filing, or concrete catalyst date provided in the release.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure risk: Ampligen may not show efficacy in larger Phase 3 trials.
- Micro-cap volatility: AIM has a $2M market cap and is prone to large price swings.
- No near-term catalyst: The next milestone is not until June 2026, leaving a long period of uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294960 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers